RxDoctor Payments Data

Kathryn Muschick

Pediatrics · Greenville, SCNPI 1417434655

Payments from drug & device makers

$1,133in general payments, 2019–2025

Across 27 payments — averaging $41.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$264
  • Global Blood Therapeutics, Inc.$258
  • CSL Behring$213
  • Agios Pharmaceuticals, Inc.$141
  • Puma Biotechnology, Inc.$94
  • Sanofi$76
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$1,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer9$264
Global Blood Therapeutics, Inc.4$258
CSL Behring4$213
Agios Pharmaceuticals, Inc.1$141
Puma Biotechnology, Inc.1$94
Sanofi3$76
Pierre Fabre Pharmaceuticals, Inc.2$33
Vertex1$22
AstraZeneca1$18
Novo Nordisk1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,133 in reported general payments places this provider in the 80th percentile of 969 pediatrics providers in South Carolina.

See all pediatrics providers in South Carolina

Medicare billing

Part B allowed, 2024
$7,305
Medicare patients
22
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxbrytaVoxelotor75$998,223
Deferasirox12$51,048
EliquisApixaban13$7,399
Buprenorphine15$3,468
Hydroxyurea35$985
Famotidine17$295
Cyclobenzaprine Hcl37$221
Promethazine Hcl18$181
Gabapentin15$179
Amitriptyline Hcl14$168
Pregabalin15$135
Montelukast Sodium15$102
Penicillin V Potassium12$74
Lisinopril12$55
Duloxetine Hcl11$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Global Blood Therapeutics, Inc.Oxbryta$258$998,22375 claims
PfizerEliquis$264$7,39913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 969 pediatrics providers in South Carolina.

Other pediatrics in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →